Edward Echevarria Torres
Endocrinology, Diabetes & Metabolism · Las Vegas, NVNPI 1487116844
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in NV, where the typical reported total is $4,060.
Across 62 payments — averaging $58.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$742
- Chiesi USA, Inc.$478
- Sanofi-aventis U.S. LLC$418
- Amgen$263
- Boehringer Ingelheim$260
- Kyowa Kirin, Inc.$248
- plus $1K from 14 others
What the payments were for
- Food & beverage$3,652100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 17 | $742 |
| Chiesi USA, Inc. | 4 | $478 |
| Sanofi-aventis U.S. LLC | 6 | $418 |
| Amgen(2 entities) | 3 | $263 |
| Boehringer Ingelheim | 4 | $260 |
| Kyowa Kirin, Inc. | 2 | $248 |
| Bayer | 3 | $248 |
| Neurocrine Biosciences, Inc. | 1 | $138 |
| Xeris Pharmaceuticals, Inc. | 1 | $135 |
| Recordati_rare_diseases_inc. | 1 | $130 |
| Madrigal Pharmaceuticals | 1 | $125 |
| Averitas Pharma Inc. | 1 | $119 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $76 |
| Johnson & Johnson | 4 | $70 |
| E.r. Squibb & Sons, L.L.C. | 3 | $55 |
| Novo Nordisk | 2 | $40 |
| PBG Puerto Rico LLC | 2 | $36 |
| Corcept Therapeutics | 1 | $30 |
| Amphastar Pharmaceuticals, Inc. | 1 | $21 |
| Eli Lilly Export S.A. Puerto Rico Branch | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYCAPSSA$272
- MYALEPT$206
- CRENESSITY$138
- RECORLEV$135
- ISTURISA$130
- JARDIANCE$125
- RESMETIROM$125
- Adempas$125
- TEPEZZA$124
- Repatha$122
- Qutenza$119
- TZIELD$115
- EMBLEM MRI S-ICD$112
- WATCHMAN Access System$110
- Kerendia$104
How this compares
$3,652 in reported general payments places this provider in the 45th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
See all endocrinology, diabetes & metabolism providers in Nevada →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 35 | $51,685 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 15 | $924 |
| Levothyroxine Sodium | 21 | $252 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $40 | $51,68535 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
Other endocrinology, diabetes & metabolism in Las Vegas
- Samer NakhleLas Vegas$466K
- Chakravarthy KannanLas Vegas$144K
- Michael UzmannLas Vegas$77K
- Molouk RahnemaLas Vegas$73K
- Nicholas VernettiLas Vegas$62K
- Firhaad IsmailLas Vegas$47K
- Bijan AhrariLas Vegas$47K
- Freddie ToffelLas Vegas$33K
- Serena KlughLas Vegas$14K
- Betsy PalalLas Vegas$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.